NCT01762462View on ClinicalTrials.gov

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Hepatic Impairment
Interventions
DRUG

SAR302503

"Pharmaceutical form:capsule~Route of administration: oral"

Trial Locations (3)

32809

Investigational Site Number 840002, Orlando

33014

Investigational Site Number 840003, Miami

37920

Investigational Site Number 840001, Knoxville

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY